| Bioactivity | Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma[1][2][3]. |
| Target | IL-13. |
| In Vivo | Anrukinzumab (IMA-638; 10 mg/kg; intravenous infusion; single) 减少食蟹猕猴肺部炎症模型中的肺部炎症[1]。 Animal Model: |
| Name | Anrukinzumab |
| CAS | 910649-32-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bree A, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol. 2007 May;119(5):1251-7. [2]. Reinisch W, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 2015 Jun;64(6):894-900. [3]. Elias JA, et al. IL-13 in asthma. The successful integration of lessons from mice and humans. Am J Respir Crit Care Med. 2011 Apr 15;183(8):957-8. |